Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current management of malignant hypercalcaemia.

J C Stevenson1

  • 1Cavendish Clinic, London, England.

Drugs
|August 1, 1988
PubMed
Summary
This summary is machine-generated.

Malignant hypercalcaemia, a dangerous cancer complication, stems from increased bone calcium release and kidney retention. Effective management is crucial for cancer treatment success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of hormone replacement therapy on intervertebral disc height.

Climacteric : the journal of the International Menopause Society·2023
Same author

Cardiometabolic health in premature ovarian insufficiency.

Climacteric : the journal of the International Menopause Society·2021
Same author

HRT and breast cancer: a million women ride again.

Climacteric : the journal of the International Menopause Society·2020
Same author

The menopausal hot flush: a review.

Climacteric : the journal of the International Menopause Society·2017
Same author

Cardiovascular risk assessment in women - an update.

Climacteric : the journal of the International Menopause Society·2016
Same author

Bisphosphonate drug holidays--when, why and for how long?

Climacteric : the journal of the International Menopause Society·2015
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Nephrology
  • Endocrinology

Background:

  • Malignant hypercalcaemia is a life-threatening complication of cancer.
  • Pathogenesis involves increased bone calcium resorption and renal calcium reabsorption.
  • Enhanced intestinal absorption may occur in reticuloendothelial malignancies.

Purpose of the Study:

  • To outline the mechanisms of malignant hypercalcaemia.
  • To describe acute and long-term management strategies.
  • To emphasize the importance of controlling hypercalcaemia for overall cancer treatment.

Main Methods:

  • Review of pathogenic mechanisms of hypercalcaemia in malignancy.
  • Description of acute treatment modalities including hydration, calcitonin, and diphosphonates.

Related Experiment Videos

  • Discussion of long-term management strategies and integration with antitumour therapy.

    • Main Results:

    • Identified primary mechanisms: bone calcium mobilization and renal calcium retention.
    • Noted potential role of intestinal calcium absorption in specific malignancies.
    • Highlighted the critical need for prompt and sustained control of serum calcium levels.

    Conclusions:

    • Effective management of malignant hypercalcaemia is essential for achieving primary cancer treatment goals.
    • Acute management focuses on rapid serum calcium reduction.
    • Long-term control requires sustained measures alongside specific antitumour therapies.